Chul Kim: Jennifer A. Marks on KRAS mutant NSCLC at DC Lung 24
Chul Kim, Associate Professor at Georgetown University, shared a post on X:
“Great talk by Dr. Jennifer A. Marks on KRAS mutant NSCLC. Two approved agents for KRAS G12C: sotorasib & adagrasib.
Many agents in development for both KRAS G12C and non G12C.
Rapidly evolving field.”
Dr. Chul Kim holds the position of Associate Professor at Georgetown University, specializing in thoracic oncology. Dr. Kim was recognized with the Norman Rales Young Investigator Award by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) in 2018. In 2021, he was presented with the John F. Potter, MD, Award by Georgetown Lombardi Comprehensive Cancer Center. Dr. Kim actively contributes to the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He has authored more than 60 articles in reputable peer-reviewed journals.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023